Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

An influx of late-phase programs has prompted Genmab to reassess its bets. | An influx of late-phase programs has prompted Genmab to reassess its bets. The biotech is axing three early-stage clinical ...

CHICAGO — A real-world study of the ocular side effects of the gynecological cancer treatment mirvetuximab (Elahere) has ...

Q3 2024 Earnings Call Transcript October 30, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $3, expectations ...

Despite the firm again raising its revenue and GAAP guidance, we’ve made only minor changes to our model in the long run.

AbbVie Inc. ABBV reported adjusted earnings of $3.00 per share for the third quarter of 2024, beating the Zacks Consensus ...

AbbVie's Q3 earnings surpassed expectations with $3.00 EPS and $14.46 billion in revenue. Skyrizi and Rinvoq led growth; AbbVie also raised 2024 EPS guidance.

Circle to Search is coming to compatible phones with OxygenOS 15 The update also adds new boot animation, icons, and shelf card choices OxygenOS 15 introduces Gemini-powered AI Notes ...

More than 55% of patients taking Elahere, an ovarian cancer approved in 2022, may experience vision loss, according to a new study. The FDA's label for Elahere (mirvetuximab soravtansine ...

As the target FolRα has been validated by approval and successful launch of AbbVie's (ABBV) Elahere (acquired ImmunoGen for $10 billion last year), Sutro thinks its "best in class" candidate ...